



Donor 4455

Genetic Testing Summary

Fairfax Cryobank recommends reviewing this genetic testing summary with your healthcare provider to determine suitability.

Last Updated: 06/28/21

Donor Reported Ancestry: Scottish, Welsh, Irish

Jewish Ancestry: No

Genetic Test*	Result	Comments/Donor's Residual Risk**
Chromosome analysis (karyotype)	Normal male karyotype	No evidence of clinically significant chromosome abnormalities
Hemoglobin evaluation	Normal hemoglobin fractionation and MCV/MCH results	Reduced risk to be a carrier for sickle cell anemia, beta thalassemia, alpha thalassemia trait (aa/-- and a-/a-) and other hemoglobinopathies
Cystic Fibrosis (CF) carrier screening	Negative by genotyping of 99 mutations in the CFTR gene	1/310
Spinal Muscular Atrophy (SMA) carrier screening	Negative for deletions of exon 7 in the SMN1 gene	1/700
Hb Beta Chain-Related Hemoglobinopathy (including Beta Thalassemia and Sickle Cell Disease) by genotyping	Negative for 28 mutations tested in the HBB gene	1/1500 for Beta-Thalassemia <1/500 for Sickle Cell
Tay Sachs Enzyme Analysis	Non-carrier by Hexosaminidase A testing	

*No single test can screen for all genetic disorders. A negative screening result significantly reduces, but cannot eliminate, the risk for these conditions in a pregnancy.

**Donor residual risk is the chance the donor is still a carrier after testing negative.

**Results Recipient**Fairfax Cryobank
Attn: Dr. Harvey Stern

Report Date: 06/22/2012

MaleName: DONOR 4455
DOB: [REDACTED]
Ethnicity: Northern European
Sample Type: EDTA Blood
Date of Collection: 06/18/2012
Date Received: 06/20/2012
Barcode: [REDACTED]
Indication: No family history
(screening)**Female**

Not tested

Counsyl Test Results

The Counsyl test (**Fairfax Cryobank Fundamental Panel**) uses targeted DNA mutation analysis to simultaneously determine the carrier status of an individual for **128 variants** associated with **4 diseases**. This report indicates which mutations, if any, were detected for each mutation panel. Because only select mutations are tested, the percentage of carriers detected varies by ethnicity. A full list of mutations tested is given on page 2. A negative test result does not eliminate the possibility that the individual is a carrier. Interpretation is given as an estimate of the risk of conceiving a child affected with a disease, which is based on reported ethnicity, the test results, and an assumption of no family history.*

**DONOR 4455**

DONOR 4455's DNA test shows that he is not a carrier of any disease-causing mutation tested.

**Partner**

The reproductive risk presented is based on a hypothetical pairing with a partner of the same ethnic group.

Reproductive Risk Summary

No increased reproductive risks to highlight. Please refer to the following pages for detailed information about the results.

Clinical notes:

- Individuals of African, Southeast Asian, and Mediterranean ancestry are at increased risk for being carriers for hemoglobinopathies and may also benefit from carrier testing by CBC and hemoglobin electrophoresis or HPLC. *ACOG Practice Bulletin No. 78. Obstet Gynecol 2007;109:229-37.*
- If necessary, patients can discuss residual risks with their physician or a genetic counselor. To schedule a free appointment to speak with a genetic counselor about these results, please visit counsyl.com/counseling/.

ENTERED
NP 07.09.12**Lab Directors:**

Jessica Jacobson, MD

William Seltzer, PhD, FACMG

* **Limitations:** In an unknown number of cases, nearby genetic variants may interfere with mutation detection. The test is not validated for detection of homozygous mutations, and although rare, asymptomatic individuals affected by the disease may not be genotyped accurately. Other possible sources of diagnostic error include sample mix-up, trace contamination, and technical errors. The reproductive risk summary is provided as an aid to genetic counseling. Inaccurate reporting of ethnicity may cause errors in risk calculation. For the purposes of risk calculations, it is assumed that mutations within the same gene are on different chromosomes.

This test was developed and its performance characteristics determined by Counsyl, Inc. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. These results are adjunctive to the ordering physician's workup. CLIA Number: #05D1102604.



Male

Name: DONOR 4455

DOB [REDACTED]

Female

Not tested

Mutations Tested

Beta Thalassemia - Gene: HBB. Variants (27): K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-745, IVS-II-850, IVS-I-6, IVS-I-110, IVS-I-5, IVS-I-1(G>A), -88C>T, -28A>G, -29A>G, Lys8fs, Phe71fs, IVS-II-849(A>C), IVS-II-849(A>G), Gly24 T>A, -87C>G, Hb C, W15X, Gly16fs, Glu6fs, Hb E, Hb D-Punjab, Hb O-Arab. Detection rate: Northern European 83%.

Cystic Fibrosis - Gene: CFTR. Variants (99): G85E, R117H, R334W, R347P, A455E, G542X, G551D, R553X, R560T, R1162X, W1282X, N1303K, F508del, I507del, 2184delA, 3659delC, 621+1G>T, 711+1G>T, 1717-1G>A, 1898+1G>A, 2789+5G>A, 3120+1G>A, 3849+10kbC>T, E60X, R75X, E92X, Y122X, G178R, R347H, Q493X, V520F, S549N, P574H, M1101K, D1152H, 2143delT, 394delTT, 444delA, 1078delT, 3876delA, 3905insT, 1812-1G>A, 3272-26A>G, 2183AA>G, S549R(A>C), R117C, L206W, G330X, T338I, R352Q, S364P, G480C, C524X, S549R(T>G), Q552X, A559T, G622D, R709X, K710X, R764X, Q890X, R1066C, W1089X, Y1092X, R1158X, S1196X, W1204X(c.3611G>A), Q1238X, S1251N, S1255X, 3199del6, 574delA, 663delT, 935delA, 936delTA, 1677delTA, 1949del84, 2043delG, 2055del9>A, 2108delA, 3171delC, 3667del4, 3791delC, 1288insTA, 2184insA, 2307insA, 2869insG, 296+12T>C, 405+1G>A, 405+3A>C, 406-1G>A, 711+5G>A, 712-1G>T, 1898+1G>T, 1898+5G>T, 3120G>A, 457TAT>G, 3849+4A>G, Q359K/T360K. Detection rate: Northern European 91%.

Sickle Cell Disease - Gene: HBB. Variants (28): Hb S, K17X, Q39X, Phe41fs, Ser9fs, IVS-II-654, IVS-II-745, IVS-II-850, IVS-I-6, IVS-I-110, IVS-I-5, IVS-I-1(G>A), -88C>T, -28A>G, -29A>G, Lys8fs, Phe71fs, IVS-II-849(A>C), IVS-II-849(A>G), Gly24 T>A, -87C>G, Hb C, W15X, Gly16fs, Glu6fs, Hb E, Hb D-Punjab, Hb O-Arab. Detection rate: Northern European 70%.

Spinal Muscular Atrophy - Gene: SMN1. Variants (1): Exon 7 deletion. Detection rate: Northern European 95%.

ENTERED



Male

Name: DONOR 4455

DOB: [REDACTED]

Female

Not tested

Risk Calculations

Below are the full test results for all diseases on the panel. Listed in this section is the patient's post-test risk of being a carrier of each disease as well as the odds that his future children could inherit each disease. A negative result does not rule out the possibility of being a carrier of untested mutations. Estimates of post-test carrier risk assume a negative family history.

Disease	Donor 4455 Residual Risk	Post-test Reproductive Risk	Pre-test Reproductive Risk
Beta Thalassemia	1 in 1,500	< 1 in 1,000,000	1 in 250,000
Cystic Fibrosis	1 in 310	1 in 34,000	1 in 3,000
Sickle Cell Disease	< 1 in 500	< 1 in 1,000,000	< 1 in 1,000,000
Spinal Muscular Atrophy	1 in 700	1 in 97,000	1 in 4,800